AngioDynamics (ANGO) reported Q4 2025 revenue of $80.16 million, surpassing estimates of $74.26 million by 8% and increasing 12.9% from $70.98 million a year ago.
The company posted an adjusted loss of $0.03 per share, beating the estimated loss of $0.12 and improving from a loss of $0.06 per share in the same quarter last year. For FY 2026, AngioDynamics expects earnings to range from a loss of $0.35 to $0.25 per share, wider than the estimated loss of $0.23.
Revenue is projected between $305.00 million and $310.00 million, slightly above the estimate of $304.86 million.
